U.S. acellular dermal matrices (ADMs) are a type of grafting material produced from donated human dermal tissue. ADMs are increasingly being used for breast reconstruction and other soft tissue repairs due to their biocompatibility and ability to integrate into the body. By optimizing tissue remodeling and reducing complications, ADMs help minimize additional surgeries and related costs.
The global U.S. acellular dermal matrices Market is estimated to be valued at US$ 2783.32 million in 2023 and is expected to exhibit a CAGR of 5.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
Reducing healthcare costs through lower treatment times and readmission rates presents a major market opportunity for providers of ADMs. By promoting optimal healing and recovery, ADMs help accelerate patients' return to normal activities and work. This translates to shorter hospital stays and reduced need for additional procedures or care in rehabilitation facilities. As healthcare providers face mounting pressure to rein in costs, ADMs that demonstrate tangible cost-saving benefits through lower overall resource utilization are poised to gain greater acceptance in the U.S. market.
Porter's Analysis
Threat of new entrants: Low barriers for new entrants due to the low distribution and manufacturing costs. However, the industry is dominated by some well-established key players reducing threats from new entrants.
Bargaining power of buyers: The bargaining power of buyers is moderate as there are a few alternative providers and the products are differentiated. However, buyers have low switching costs.
Bargaining power of suppliers: The suppliers have moderate bargaining power as the key raw materials required are available from multiple suppliers globally and they are well-established.
Threat of new substitutes: The threat of new substitutes is low as there are limited substitutes for acellular dermal matrices used in plastic and reconstructive surgeries currently.
Competitive rivalry: The industry sees high competitive rivalry among the key established players globally to gain more market share through new product developments and strategic collaborations.
SWOT Analysis
Strengths: Established brand names, strong distribution network, product innovation capabilities.
Weaknesses: High R&D costs, stringent regulatory approvals, dependency on reimbursements.
Opportunities: Growing demographics for reconstructive procedures, demand in emerging markets.
Threats: Price controls, new regulations, technology disruption.
Key Takeaways
The U.S. Acellular Dermal Matrices Market Growth is expected to witness high at a CAGR of 5.5% during the forecast period of 2023-2030. The market size is estimated to reach US$ 4,413.36 Mn by 2030 from US$ 2,783.32 Mn in 2023.
Regional analysis: The South region dominates the U.S. market currently with over 35% share due to higher medical expenditures and availability of advanced healthcare facilities. The region is expected to maintain its leading position throughout the forecast period driven by the presence of key manufacturers in the region and rising cosmetic surgeries.
Key players: Key players operating in the U.S. acellular dermal matrices market are Biomet, Inc., Wright Medical Technology, Inc., Smith & Nephew Plc, and Stryker. Biomet, Inc. holds the largest market share currently owing to its strong brand presence and wide product portfolio. Stryker is focusing on new product launches and strategic collaborations to strengthen its market position in the coming years.
Explore more information on this topic, Please visit-https://www.dailyprbulletin.com/u-s-acellular-dermal-matrices-market-share-size-and-growth-share-trends-analysis-demand-forecast/
Explore more trending article related this topic:
Comments
0 comment